- Milciclib was in-licensed from Nerviano Medical Sciences S.r.l, in January 2015. Tiziana is developing Milciclib as a potential treatment for hepatocellular carcinoma, or HCC.
- Milciclib is an orally-available, small molecule, broad-spectrum inhibitor of cyclin-dependent kinases (CDKs), as well as several other protein kinases responsible for controlling cell growth and replication.
- Milciclib has an unusual kinase inhibitory profile making it active against other receptors such as, tyrosine kinase, Src family and splicing kinases, which play a role in cell growth and transformation from normal to cancerous cell types.
- The main cell cycle targets of milciclib are CDKs 2/Cyclin A as well as CDK1, CDK4 and CDK5 resulting in a block in the G1 (gap) phase of the cell cycle.
- Milciclib has a novel ability to reduce levels of microRNAs, miR-221 and miR-222, believed to be linked to the development of increased blood supply (angiogenesis) in cancer tumors.